| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/10/2003 | WO2002028889A3 Haemophilus influenzae antigens and corresponding dna fragments |
| 04/10/2003 | WO2002026980A3 Human ion-exchanger proteins and polynucleotides encoding t he same |
| 04/10/2003 | WO2002012283A3 Disintegrin homologs, zsnk10, zsnk11, and zsnk12 |
| 04/10/2003 | WO2002010202A3 G-protein coupled receptors and nucleic acids encoding same |
| 04/10/2003 | WO2002008396A3 Human proteases |
| 04/10/2003 | WO2002000174A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 04/10/2003 | WO2001083693A3 Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses |
| 04/10/2003 | US20030070184 Ligands for discoidin domain receptor tyrosine kinases and complexes thereof |
| 04/10/2003 | US20030069431 Method for synthesis of perindopril and its pharmaceutically acceptable salts |
| 04/10/2003 | US20030069408 Nucleotide sequences coding protein for use in the treatment of periodontal diseases; for use as wound healing agents |
| 04/10/2003 | US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders |
| 04/10/2003 | US20030069405 70 human secreted proteins |
| 04/10/2003 | US20030069404 Nucleotide sequences coding polypeptide for use in the prevention and treatment of microorganismal infections |
| 04/10/2003 | US20030069403 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030069401 Osteogenic devices |
| 04/10/2003 | US20030069395 Serum albumin conjugate for use in the transfer and delivery of therapeutic agent to target |
| 04/10/2003 | US20030069394 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030069392 Cationic lipids |
| 04/10/2003 | US20030069391 Process for preparing glycopeptide phosphonate derivatives |
| 04/10/2003 | US20030069301 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 04/10/2003 | US20030069228 Capase inhibitors; antiinflammatory agents |
| 04/10/2003 | US20030069222 Used as anti-viral agents against the HIV-1 and HIV-2 viruses. |
| 04/10/2003 | US20030069221 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 04/10/2003 | US20030069205 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate. |
| 04/10/2003 | US20030069202 Compositions, kits, and methods for promoting defined health benefits |
| 04/10/2003 | US20030069201 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 04/10/2003 | US20030069200 Use of glucosylceramide synthesis inhibitors in brain cancertherapy |
| 04/10/2003 | US20030069197 Probes and primers can be employed in diagnostic kits, in identifying or isolating mammalian PTTG nucleic acid, and in detecting a pathological mass associated with PTTG expression. |
| 04/10/2003 | US20030069196 Ameliorating a symptom of an ischemic disorder or injury comprising administering a 200 gene product to ameliorate the symptom of the ischemic disorder or injury. |
| 04/10/2003 | US20030069195 Suppression of polymorphic alleles |
| 04/10/2003 | US20030069189 Administering an NF-kappa B activation inhibitor that is a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with activation of NF-kappa B via the ubiquitin proteasome pathway |
| 04/10/2003 | US20030069187 Naturally occurring novel elastin derived oligopeptides, having the formula AFP, VPG and AGIP; determining the severity of a disease characterized by elevated activity of an elastolytic serine protease |
| 04/10/2003 | US20030069186 Chimeric natriuretic peptides |
| 04/10/2003 | US20030069185 Use of gents which bind G proteins for treating septic shock |
| 04/10/2003 | US20030069184 Oligopeptides obtained from the MUCD1 domain of the saliva mucin glycoprotein MUC7 have a net positive charge |
| 04/10/2003 | US20030069183 Lyophilized HGF preparations |
| 04/10/2003 | US20030069182 Protein formulations |
| 04/10/2003 | US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 04/10/2003 | US20030069180 Compositions and methods for the therapy and diagnosis of colon cancer |
| 04/10/2003 | US20030069179 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030069178 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030069177 Contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor. |
| 04/10/2003 | US20030069176 Methods for treating neurological injuries and disorders |
| 04/10/2003 | US20030069175 A cyclic peptide, e.g., cyclic (Tyr-Gly-Phe-Gly-Gly) useful for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation, repairing fractures, healing wounds, grafting intraosseous implants, etc. |
| 04/10/2003 | US20030069174 Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation |
| 04/10/2003 | US20030069171 Mixture of glucosamine salt, chondroitin sulfate, collagen and sodium hyaluronate for treating bone disorders |
| 04/10/2003 | US20030069169 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
| 04/10/2003 | US20030068821 Method for expression of small RNA molecules within a cell |
| 04/10/2003 | US20030068820 Hematopoietic stem cell proliferating agents |
| 04/10/2003 | US20030068806 Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same |
| 04/10/2003 | US20030068798 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cell proliferative and tumor disorders |
| 04/10/2003 | US20030068797 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cell proliferative and tumor disorders |
| 04/10/2003 | US20030068796 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cell proliferative and tumor disorders |
| 04/10/2003 | US20030068795 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cell proliferative and tumor disorders |
| 04/10/2003 | US20030068794 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cell proliferative and tumor disorders |
| 04/10/2003 | US20030068793 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030068792 Therapeutic agent for use in the treatment of infections and cancer disorders |
| 04/10/2003 | US20030068787 Antibody specifically binding cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 04/10/2003 | US20030068785 Modified factor VIII |
| 04/10/2003 | US20030068691 Peptide for use in the treatment and diagnosis of nervous system, epilepsy and stroke |
| 04/10/2003 | US20030068678 WISP polypeptides and nucleic acids encoding same |
| 04/10/2003 | US20030068673 Atherosclerosis susceptibility gene locus 1 (Athsq1) and atherosclerosis susceptibility gene locus 2 (Athsq2) |
| 04/10/2003 | US20030068671 Polypeptide for use in the prevention, treatment and diagnosis of infections, eating, nervous system, blood, immunological and diabetic disorders |
| 04/10/2003 | US20030068661 Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| 04/10/2003 | US20030068659 ICAM-4 materials and methods |
| 04/10/2003 | US20030068648 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030068647 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of nervous system and cancer disorders |
| 04/10/2003 | US20030068641 Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| 04/10/2003 | US20030068628 Nucleotide sequences coding for variable regions of beta chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| 04/10/2003 | US20030068627 Nucleic acids, proteins, and antibodies |
| 04/10/2003 | US20030068623 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/10/2003 | US20030068618 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | US20030068361 For treating hyperglycemia and related disorders |
| 04/10/2003 | US20030068327 Compositions and methods for the diagnosis and threatment of herpes simplex virus infection |
| 04/10/2003 | US20030068325 A peptide immunogen of about 20 to 100 amino acids long comprising: a helper T cell (Th) epitope, an N-terminal fragment of A beta 1-42 peptide, consisting from 10-28 amino acid residues |
| 04/10/2003 | US20030068323 Hybrid compositions for intracellular targeting |
| 04/10/2003 | US20030068321 Methods of effecting neuronal activity |
| 04/10/2003 | US20030068316 An antibody that interacts preferentially with soluble, non-fibrillar oligomeric assemblies of amyloid beta derived diffusible ligands; applied for diagnosis, prevention and treatment of neurodegenerative diseases |
| 04/10/2003 | US20030068314 Anti-diarrheal and method for using the same |
| 04/10/2003 | US20030068313 A therapeutic agent for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 comprising a C-type natriuretic peptide activating guanylyl cyclase B |
| 04/10/2003 | US20030068312 Novel human dickkopf-related protein and nucleic acid molecules and uses therefor |
| 04/10/2003 | US20030068310 Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical PKM activity |
| 04/10/2003 | US20030068307 Administering a target cell-specific adenovirus vector, comprising an adenoviral gene essential for replication under transcriptional control of a target cell-specific transcriptional regulatory element and an anticancer agent |
| 04/10/2003 | US20030068302 Optimal compositions and methods thereof for treating HCV infections |
| 04/10/2003 | US20030068301 Nucleic acid molecules, including antisense and enzymatic nucleic acid molecules which modulate synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus |
| 04/10/2003 | US20030068299 Administering promoter of T-cell expansion and inducer of CD40 stimulation in synergistically effective amounts to treat or prevent pathologic state in mammal; cancer therapy |
| 04/10/2003 | US20030068298 Cytokine immunotherapy followed by neurosurgical intervention for total resection of intracerebral tumor; cytokine therapy comprises intravenous administration of lymphokine-activated killer cells with recombinant yeast interleukin-2 |
| 04/10/2003 | US20030068297 Contains cell growth enhancers to increase growth rate of skin cells, nutrients to support log phase growth of skin cells, extracellular matrix proteins, stimulators of extracellular matrix proteins, penetration enhancers; wound healing |
| 04/10/2003 | US20030068280 Treatment of respiratory diseases |
| 04/10/2003 | US20030068279 Dispersible pharmaceutical-based dry powder composition comprising a therapeutically effective amount of pharmaceutical in combination with a pharmaceutically acceptable carrier |
| 04/10/2003 | US20030068277 Particles for inhalation having sustained release properties |
| 04/10/2003 | US20030067396 Electronic vehicle toll collection system and method |
| 04/10/2003 | CA2768340A1 Copolymers for suppression of autoimmune diseases, and methods of use |
| 04/10/2003 | CA2464690A1 Muteins of apolipoprotein d |
| 04/10/2003 | CA2463404A1 Fragements of heat shock proteins and their use |
| 04/10/2003 | CA2462802A1 Nutrient medium for maintaining neural cells in injured nervous system |
| 04/10/2003 | CA2462796A1 Gene regulatory peptides |
| 04/10/2003 | CA2462795A1 Secreted proteins |
| 04/10/2003 | CA2462790A1 Ul16 binding protein 4 |
| 04/10/2003 | CA2462672A1 Neuropilin/vegf c/vegfr 3 materials and methods |